Johnson & Johnson (JNJ) EBITDA Margin (2009 - 2026)
Johnson & Johnson (JNJ) posted EBITDA Margin of 28.21% for Q2 2026, up 6.68% sequentially from 26.44% in Q1 2026, and up 22.0% YoY from 23.12% in Q2 2025.
Johnson & Johnson (JNJ) EBITDA Margin (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported EBITDA Margin for 18 years, with the latest figure at 28.21% in Q2 2026.
- Quarterly EBITDA Margin rose 22.0% year-over-year to 28.21% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 26.59% (up 291.0% YoY) and the FY2025 annual result came in at 26.93%, up 327.0% from the prior year.
- EBITDA Margin grew to 28.21% in Q2 2026 per JNJ's latest filing, from 26.44% in the prior quarter.
- Over five years, EBITDA Margin peaked at 48.19% in Q1 2023 and troughed at 15.98% in Q4 2024.
- A 5-year average of 26.36% and a median of 26.95% in 2023 frame the typical range for EBITDA Margin.
- The widest YoY moves for EBITDA Margin: up 782 bps in 2023, down 2832 bps in 2023.
- Over 5 years, EBITDA Margin stood at 26.5% in 2022, then fell by 25 bps to 19.87% in 2023, then retreated by 20 bps to 15.98% in 2024, then jumped by 40 bps to 22.42% in 2025, then advanced by 26 bps to 28.21% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 28.21%, 26.44%, and 22.42% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 28.37% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 5.72% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 124.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 28.21% |
| Mar 29, 2026 | 26.44% |
| Dec 28, 2025 | 22.42% |
| Sep 28, 2025 | 29.31% |
| Jun 29, 2025 | 27.99% |
| Mar 30, 2025 | 28.24% |
| Dec 29, 2024 | 15.98% |
| Sep 29, 2024 | 22.42% |
| Jun 30, 2024 | 28.82% |
| Mar 31, 2024 | 27.63% |
| Dec 31, 2023 | 19.87% |
| Oct 1, 2023 | 26.88% |
| Jul 2, 2023 | 27.01% |
| Apr 2, 2023 | 27.36% |
| Jan 1, 2023 | 48.19% |
| Oct 2, 2022 | 26.50% |
| Jul 3, 2022 | 19.19% |
| Apr 3, 2022 | 21.94% |
| Oct 3, 2021 | 28.31% |
| Jul 4, 2021 | 26.60% |